SLU Researchers Enroll Participants in 2-in-1 COVID and Flu Vaccine Clinical Trial
ST. LOUIS – Saint Louis University’s Center for Vaccine Development is participating in a clinical study for an investigational vaccine being developed against influenza and COVID developed by Pfizer, which is funding this research.
While there are licensed vaccines and treatments for both influenza and COVID, the current vaccines have been given as separate shots. This study looks at whether both vaccines can be combined into one shot without affecting the antibody response to either vaccine.
Sarah George, M.D., professor of infectious diseases at SLU School of Medicine and a researcher in SLU’s Vaccine Center. SLU file photo.
Sarah George, M.D., professor of infectious diseases at SLU School of Medicine and a researcher in SLU’s Vaccine Center, will assist in studying whether the combined vaccine induces the body to make antibodies to both influenza and COVID, compared with giving both vaccines separately.
“Since it looks like COVID will be with us for the long haul, just as flu is, it’s important to see if we can combine both vaccines into one shot without compromising immunity of both,” George said. “It’s vital that we continue to work to develop combined vaccines that can protect all of us, especially the vulnerable, from these illnesses.”
The phase 3 clinical trial is being conducted at over 200 sites in the United States, including Saint Louis University. SLU researchers are recruiting around 150 healthy adults 18 through 64 years of age who have not had a flu or COVID vaccine in the past 6 months. Overall, the study will recruit 9,000 volunteers and will last about a year. Each volunteer will have 3 study visits.
To learn more about vaccine research being conducted at Saint Louis University, call 314-977-6333 or email vaccine@slu.edu. For more information on this study, please visit the ClinicalTrials.gov website link here.
Latest Newslink
- SLU Valentine School of Nursing Doctoral Students Selected as 2024-2026 Jonas ScholarsJonas Nursing, a leading supporter of doctoral nursing education in the U.S., and the American Association of Colleges of Nursing, recently announced that Austin DesJardin and Joy Stark, Ph.D. students at Saint Louis University, have been selected as Jonas Scholars for the program's 2024-2026 cohort.
- SLU Professor to Teach Criminology in India as Part of Fulbright Scholars ProgramDyan McGuire, J.D., Ph.D., director and associate professor of criminology and criminal justice, has received a Fulbright U.S. Scholar Program award to teach criminology and criminal justice in India for the 2024-25 academic year.
- SLU Partners with Washington University on Midwest Center for AIDS ResearchIn a bid to jump-start the campaign against HIV in the region, Saint Louis University, in partnership with Washington University School of Medicine, will establish the Midwest Developmental Center for AIDS Research with funding from the National Institutes of Health (NIH). The center, slated to open in September, will aim to create a platform for researchers and public health workers to collaborate and coordinate their efforts to fight the HIV epidemic together.
- SLU Researchers Invite Living Kidney Donors and Recipients to Join NIH-funded Study to Overcome Disparities in Kidney Disease, TransplantationSaint Louis University School of Medicine researchers led by Krista Lentine, M.D., Ph.D., professor of medicine, will assess how the use of genetic testing may mitigate racial disparities in the health outcomes of people with chronic kidney disease, including organ donors and transplant recipients.
- Saint Louis University To Offer Free Psychological Assessments for St. Louis City ResidentsSaint Louis University's Psychological Services Center, in partnership with the St. Louis Mental Health Board, will begin offering free psychological assessments for St. Louis city residents on a first come, first serve basis beginning July 1.
- SLU Researcher Reports Improvements in Survival Rates in Patients with Metastatic Prostate CancerResearch from Saint Louis University School of Medicine finds improvements in survival in both Veterans and men across the country over the last 20 years in metastatic prostate cancer, which correlates with new hormonal treatments.